Prochymal® phase 2 Clinical Trial for the Treatment of Patients Experiencing a first Acute Myocardial Infarction

enrollment for this trial has been completed

This year alone, more than a half million Americans will experience their first heart attack. According to the American Heart Association, within six years of a recognized heart attack, 18% of men and 35% of women will have another heart attack. It is critical that we find new and effective ways to treat the thousands of people who enter hospital emergency rooms suffering from a heart attack and help to prevent future complications resulting from their heart attack.

The objective of this study is to evaluate the safety and efficacy of Prochymal for the treatment of symptoms associated with heart damage in patients who have just experienced their first acute myocardial infarction (AMI) or heart attack.

Trial Overview

Click Here for more information

If you have questions about this clinical program, please email us at


Osiris Therapeutics, Inc. • 7015 Albert Einstein Drive • Columbia, MD • 21046 • p(443) 545-1800 • osiris@osiris.comLegal Notice